Dayvigo Metabolism and Energy Expenditure: What Clinicians Need to Know

How Lemborexant Is Metabolized

Lemborexant is cleared almost exclusively by hepatic CYP3A4-mediated oxidation. The FDA prescribing information classifies lemborexant as a CYP3A4 substrate, and concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) can increase lemborexant area-under-the-curve by up to 4-fold, necessitating a maximum dose of 5 mg [1]. Strong inducers such as rifampin reduce exposure so substantially that co-administration is not recommended.

CYP3A4 and Minor Pathways

About 90% of an oral lemborexant dose undergoes CYP3A4 oxidation in the liver, generating at least two pharmacologically relevant metabolites: M4 (hydroxy-lemborexant) and M9 (N-desmethyl-lemborexant). M4 retains meaningful OX2R binding affinity, estimated at roughly one-third the potency of the parent compound, which prolongs the pharmacodynamic duration beyond what the parent half-life alone predicts [2]. CYP2C19 accounts for a minor secondary route (<10%), relevant only when CYP3A4 is substantially inhibited.

Absorption and Distribution

Oral bioavailability is approximately 87% under fasting conditions. A high-fat meal delays peak plasma concentration (Tmax) by roughly 2 hours but does not meaningfully alter total exposure. Volume of distribution averages 86 L, consistent with moderate tissue penetration. Plasma protein binding sits near 94%, predominantly to albumin and alpha-1 acid glycoprotein [1].

Renal excretion accounts for only about 57% of the dose (primarily as metabolites), with the remainder appearing in feces. Less than 1% of the dose is excreted as unchanged lemborexant in urine, confirming hepatic metabolism as the principal elimination route.

Half-Life and Accumulation

The terminal elimination half-life averages 17.4 hours, roughly double that of suvorexant (12 h) and much longer than zolpidem (2.5 h). At the 10 mg dose, steady-state concentrations are reached within 3 to 5 days of nightly dosing, with a modest accumulation ratio near 1.6 [1]. This extended half-life is why next-morning sedation risk persists even after the drug is subjectively "worn off."

Orexin Physiology and Energy Expenditure

Orexin (hypocretin) neurons in the lateral hypothalamus do far more than maintain wakefulness. A substantial body of preclinical evidence shows these neurons project to the ventromedial hypothalamus, the locus coeruleus, and the paraventricular nucleus, all of which modulate sympathetic outflow to brown adipose tissue (BAT) and skeletal muscle thermogenesis [3].

Brown Adipose Tissue and Orexin Signaling

Orexin-A activates OX2R on BAT-projecting sympathetic preganglionic neurons, increasing uncoupling protein-1 (UCP-1) expression and non-shivering thermogenesis. In rodent models, intracerebroventricular orexin-A infusion raises BAT temperature by 0.5 to 0.8°C within 20 minutes and elevates whole-body oxygen consumption by approximately 15% above baseline [3]. Blocking OX2R, as lemborexant does at therapeutic concentrations, attenuates this thermogenic drive during the targeted antagonism window.

Resting Energy Expenditure Implications

Sustained suppression of orexin signaling across the overnight sleep window could modestly lower the thermogenic contribution to 24-hour resting energy expenditure (REE). Chronic sleep deprivation increases orexin-A tone, raising sympathetic activity and REE; restoring normal sleep architecture via orexin blockade may therefore reduce this elevation. The net direction of change depends on whether the drug is correcting hyperactivated orexin tone (in which case REE normalizes downward) or suppressing physiologically normal orexin activity. Clinicians should not conflate a pharmacological effect on thermogenic pathways with a clinically significant caloric impact at approved doses.

Wake-Promoting Pathways and Metabolic Coupling

Orexin neurons receive inputs from peripheral energy sensors including leptin (inhibitory) and ghrelin (excitatory), creating a bidirectional link between energy availability and arousal state [4]. When lemborexant blocks OX1R and OX2R, downstream norepinephrine release from the locus coeruleus is attenuated during the drug-active period. Norepinephrine is a primary thermogenic agonist in BAT via beta-3 adrenoceptors; reduced NE release during sleep could lower overnight thermogenesis by a small but non-trivial margin.

SUNRISE-1 Trial: Efficacy, Safety, and Metabolic Signal

SUNRISE-1 (JAMA Network Open, 2019; N=1,006) was a 30-night, phase 3, double-blind, randomized controlled trial comparing lemborexant 5 mg, lemborexant 10 mg, and zolpidem CR 6.25 mg against placebo in adults with insomnia disorder [5]. The trial is the best available source for real-world metabolic signals in a human insomnia population.

Primary Efficacy Outcomes

Lemborexant 10 mg reduced subjective sleep onset latency (sSOL) by 17.0 minutes from baseline versus 5.8 minutes for placebo (P<0.001). Wake after sleep onset (WASO) fell by 42.2 minutes with lemborexant 10 mg compared with 29.3 minutes for zolpidem CR, a difference that reached statistical significance (P<0.05) [5]. These are not marginal improvements: reducing WASO by over 40 minutes represents a meaningful increase in consolidated sleep time, with downstream implications for metabolic hormone cycling.

Next-Morning Functioning and Residual Sedation

A key differentiator in SUNRISE-1 was next-morning psychomotor performance. Lemborexant 5 mg showed non-inferiority to placebo on driving simulation at 9 hours post-dose, while zolpidem CR showed statistically significant impairment at the same interval [5]. Given that residual sedation reduces spontaneous physical activity and therefore total daily energy expenditure, the cleaner next-morning profile of lemborexant may carry a modest metabolic advantage over older sedative-hypnotics.

Body Weight Observations

SUNRISE-1 was a 30-night study, a duration too short to detect clinically meaningful weight change. No statistically significant between-group difference in body weight appeared at day 30, and the trial was not powered to detect such differences [5]. Longer-term data from the 12-month SUNRISE-2 study (N=949) similarly showed no clinically meaningful mean weight change attributable to lemborexant, though individual variability in energy intake and activity confounded any metabolic interpretation [6].

Sleep Architecture, Hormonal Cascades, and Energy Balance

Improving sleep quality with lemborexant has indirect metabolic consequences through hormonal normalization. Poor sleep is tightly linked to reduced leptin (by 18% after two nights of restriction in the Spiegel et al. 2004 study, N=12) and elevated ghrelin (by 28%), creating a hormonal environment that promotes energy intake [7].

Leptin and Ghrelin Restoration

By consolidating sleep and increasing slow-wave sleep (SWS) percentage, orexin receptor antagonists may partially restore overnight leptin secretion. Suvorexant, the structurally related dual orexin receptor antagonist, increased SWS by approximately 15 to 20 minutes versus placebo in phase 3 studies [8]. Lemborexant produces a comparable, though slightly smaller, increase in SWS. More SWS generally correlates with greater overnight growth hormone release, which promotes lipolysis and lean mass preservation.

Cortisol and Sympathetic Tone

Chronic insomnia elevates 24-hour urinary cortisol and raises sympathetic nervous system tone, both of which increase gluconeogenesis and promote visceral fat deposition. Effective pharmacological sleep consolidation suppresses late-night cortisol by attenuating hypothalamic-pituitary-adrenal axis hyperactivity. In a 2019 analysis of insomnia patients treated with sedative-hypnotics (N=87), morning cortisol fell by a mean of 14% after 4 weeks of treatment, though the study did not isolate a lemborexant cohort [9].

Insulin Sensitivity and Glucose Metabolism

Fragmented sleep reduces next-morning insulin sensitivity by approximately 20 to 25% per experimental sleep restriction protocol [10]. By reducing WASO and increasing total sleep time (TST), lemborexant may modestly attenuate this glucose dysregulation. No dedicated glucose clamp or continuous glucose monitoring study with lemborexant exists in the published literature as of mid-2025, which represents a clear gap for future research.

Pharmacokinetic Drug Interactions Affecting Metabolic Patients

Many patients with metabolic comorbidities (type 2 diabetes, obesity, non-alcoholic fatty liver disease) are prescribed medications that interact with CYP3A4. This section reviews the most clinically significant interactions for the metabolic patient population.

Strong CYP3A4 Inhibitors

Fluconazole, itraconazole, ketoconazole, and clarithromycin can each increase lemborexant AUC by 2- to 4-fold. The FDA label mandates a maximum of 5 mg when any strong CYP3A4 inhibitor is co-administered [1]. Patients with type 2 diabetes on fluconazole for recurrent candidiasis are a specific at-risk group.

GLP-1 Receptor Agonists and Lemborexant

Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are not CYP3A4 substrates and do not inhibit or induce CYP enzymes. No pharmacokinetic interaction between GLP-1 receptor agonists and lemborexant is expected based on their distinct metabolic pathways [1]. Patients prescribed both medications for insomnia plus obesity or type 2 diabetes can be reassured on this specific point.

CYP3A4 Inducers in Metabolic Patients

Rifampin (sometimes used in hepatic cholestasis) and St. John's wort can reduce lemborexant AUC by up to 90%. The label advises against co-administration [1]. Carbamazepine and phenytoin, sometimes used for diabetic neuropathy, are moderate-to-strong CYP3A4 inducers that may reduce lemborexant efficacy by 40 to 70%; dose escalation to 10 mg or an alternative agent should be considered.

Hepatic Impairment and Metabolic Liver Disease

Because lemborexant is extensively hepatically metabolized, patients with significant hepatic impairment face accumulation risk. The FDA label contraindicates lemborexant in severe hepatic impairment (Child-Pugh C) and recommends the 5 mg maximum dose in moderate impairment (Child-Pugh B) [1].

NAFLD and NASH Considerations

Non-alcoholic fatty liver disease (NAFLD) affects up to 25% of U.S. Adults [11]. Mild-to-moderate NAFLD (Child-Pugh A) does not appear to meaningfully alter lemborexant pharmacokinetics based on pharmacokinetic modeling, but formal studies in this population are limited. Clinicians managing patients with NASH-related fibrosis (Child-Pugh B range) should default to 5 mg and monitor for excess next-morning sedation as a surrogate marker of accumulation.

Original Clinical Decision Framework: Lemborexant Dosing in Metabolic Comorbidity

The following tier-based approach integrates lemborexant's pharmacokinetic profile with common metabolic comorbidity patterns:

Tier 1: Standard metabolic patient (BMI 25 to 40, no significant hepatic or CYP interaction concerns). Start at 5 mg. Titrate to 10 mg at 2 weeks if sSOL remains above 30 minutes and next-morning function is intact.

Tier 2: Moderate CYP3A4 inhibitor co-administration or Child-Pugh B hepatic impairment. Cap at 5 mg. Reassess sleep diary data at 4 weeks before any modification.

Tier 3: Strong CYP3A4 inhibitor or Child-Pugh B with elevated bilirubin. Avoid lemborexant or use 5 mg with explicit documentation of the benefit-risk discussion. Consider alternative agents (e.g., low-dose doxepin, cognitive behavioral therapy for insomnia as first line).

Tier 4: Child-Pugh C, strong CYP3A4 inducer, or concurrent CNS depressants at high dose. Lemborexant is contraindicated or functionally ineffective; choose an alternative sleep intervention.

This framework is not a substitute for individual clinical judgment but provides a starting scaffold for metabolic medicine practices where polypharmacy is common.

Lemborexant Versus Other Orexin Antagonists: Metabolic Profile Comparison

Suvorexant (Belsomra) was the first dual orexin receptor antagonist approved in the United States (2014), and the two drugs share mechanistic similarities but differ in key pharmacokinetic and pharmacodynamic details relevant to metabolic patients.

Half-Life and Next-Day Function

Suvorexant's half-life is approximately 12 hours versus 17.4 hours for lemborexant. Counterintuitively, lemborexant produces less residual sedation at equieffective doses, likely because of its lower CNS receptor occupancy at trough concentrations and the activity of M4 being lower than the parent [5]. Less residual sedation means greater spontaneous daytime physical activity, which is a clinically meaningful difference in obese patients where any activity reduction worsens metabolic risk.

Dose Equivalence Considerations

Lemborexant 10 mg appears approximately equivalent in sleep maintenance benefit to suvorexant 20 mg based on indirect comparisons across phase 3 data. No head-to-head randomized trial comparing these two agents on metabolic endpoints exists as of mid-2025, though a 2022 network meta-analysis (Cochrane Database) ranked lemborexant 10 mg highest among FDA-approved hypnotics for WASO reduction [12].

Practical Prescribing Points for Metabolic Medicine Clinicians

Lemborexant prescribing in patients with obesity, type 2 diabetes, or metabolic syndrome requires attention to several converging pharmacological and physiological factors.

Dosing Timing and Metabolic Effects

The label requires administration within 30 minutes of intended bedtime with at least 7 hours remaining before planned waking [1]. In patients on basal insulin, the extended half-life means lemborexant is still pharmacologically active during the early morning glucose nadir, and sedation-related reduced activity during this window is a consideration, though no hypoglycemia interaction has been documented in clinical trials.

Monitoring Parameters

Clinicians should assess next-morning sedation at each visit using the Epworth Sleepiness Scale or a simple 0 to 10 numeric rating. Any score above 10 on the Epworth or above 6 on the numeric scale in the morning (3 to 4 hours after waking) should trigger a dose reduction to 5 mg or a CYP3A4 interaction review.

When to Stop

If a patient gains more than 3 kg over 3 months on lemborexant with no other explanation, a structured evaluation of sleep-related eating behavior (SREB) is warranted. SREB has been reported with sedative-hypnotics including Z-drugs; although it has not been specifically characterized with lemborexant in the published literature, the orexin pathway's role in appetite regulation makes it biologically plausible [13].